p53 antibody | DO-1
p53 protein expression in OS cells. wt-p53 U2-OS, U2-OS transfected with empty vector (U2-OS/e) and p53-impaired U2-OS175 cells were positive to anti-p53 that binds the transactivation site of N-terminal domain (aa20-25), with increased expression in U2-OS175 cells. U2-OS and U2-OS/e also presented accumulation of p53 phosphorylated at Ser20 residue (p-p53). MG63 and Saos-2 were negative to both antibodies. Actin was used as loading control.
From: Novello C, Pazzaglia L, Conti A, Quattrini I, Pollino S, et al. (2014)
p53-Dependent Activation of microRNA-34a in Response to Etoposide-Induced DNA Damage in Osteosarcoma Cell Lines Not Impaired by Dominant Negative p53 Expression. PLoS ONE 9(12): e114757.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti p%3(aa20-25) antibody, clone DO-1 (MCA1701) used to evaluate p53 expression in U2-OS cells by western blotting.
Response of p53siRNA U2-OS cells to etoposide. (A) Inhibition of p53 expression in p53siRNA U2-OS. Actin was used as loading control. (B) p53siRNA U2-OS were less sensitive to etoposide when compared with parental and Ctrl U2-OS;). Student’s test from three independent experiments indicated significantly higher IC50 mean values at 72 h of treatment in p53siRNA U2-OS than in Ctrl and parental U2-OS cells; p = 0.05 (C) Etoposide treatment did not induce mature miR-34a expression in p53siRNA U2-OS, as opposed to Ctrl U2-OS. (D) p53siRNA U2-OS cells presented CpG island methylation (M-MSP) of one of the two alleles of miR-34a. In Ctrl U2-OS both alleles were unmethylated. (E) p53siRNA transfection determined lengthening of G2/M phase after 48 h of etoposide treatment when compared to untreated cells. (F) Western blot of cyclin D1 and CDK4 in p53siRNA cell showed increased amount of CDK4 linked to cyclin D1 and total CDK4 after etoposide treatment when compared to control. No differences in cyclin D1 levels were seen. Ctrl = siRNA negative control duplex; C = Untreated cells; T = Etoposide treated cells.From: Novello C, Pazzaglia L, Conti A, Quattrini I, Pollino S, et al. (2014) p53-Dependent Activation of microRNA-34a in Response to Etoposide-Induced DNA Damage in Osteosarcoma Cell Lines Not Impaired by Dominant Negative p53 Expression. PLoS ONE 9(12): e114757.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti p53 (aa20-25):Biotin
Mouse anti p53 (aa20-25):FITC
Mouse anti p53 (aa20-25)
Mouse anti p53 (aa20-25):RPE
- Product Type
- Monoclonal Antibody
- Clone
- DO-1
- Isotype
- IgG2a
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| MCA1701B | P | 0.1 mg | ||||
| MCA1701F | F* | 0.1 mg | ||||
| MCA1701 | C E IP P* WB | 0.1 mg | ||||
| MCA1701PE | F* | 100 Tests |
Mouse anti Human p53 antibody, clone DO-1 recognizes the human p53 tumor suppressor protein, also known as cellular tumor antigen p53 or NY-CO-13. Clone DO-1 binds to both wild type and mutant forms of the p53 protein found in various malignancies (Kern et al. 1992). p53 is important in multicellular organisms, where it regulates cell cycle progression to allow DNA repair or apoptosis in the case of irreparably damaged cells (Haupt et al. 2003) and thus functions as a tumor suppressor that is involved in preventing cancer. Mutations in the p53 gene are found in about half the cases of human cancer (Joerger andFersht 2007)
Mouse anti Human p53 antibody, clone DO-1 recognizes an epitope at the N-terminal end of p53 between amino acids 20-25,common to isoforms 1-3 of p53.
Mouse anti Human p53 antibody, clone DO-1 recognizes an epitope at the N-terminal end of p53 between amino acids 20-25,common to isoforms 1-3 of p53.
Product Details
- Target Species
- Human
- Species Cross-Reactivity
-
Target Species Cross Reactivity Mouse Rat Bovine Cat Horse Green Monkey - N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG conjugated to Biotin - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Reconstitution
- Reconstitute with 1 ml distilled water
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Carrier Free
- Yes
- Immunogen
- Recombinant human p53.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunized BALB/c mice were fused with cells of the mouse X63Ag8.653 myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 18 months from date of despatch.
- Shelf Life
- 18 months from date of despatch.
- Shelf Life
- 18 months from date of despatch.
- Shelf Life
- 12 months from date of reconstitution.
More Information
- UniProt
- P04637 Related reagents
- Entrez Gene
- TP53 Related reagents
- Regulatory
- For research purposes only
Applications of p53 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Immunohistology - Paraffin | Neat | ||
| Flow Cytometry 1 | 1/2 | 1/10 | |
| ELISA | |||
| Immunohistology - Frozen | |||
| Immunohistology - Paraffin 1 | 1/25 | ||
| Immunoprecipitation | |||
| Western Blotting | 1/1000 | ||
| Flow Cytometry 1 | Neat |
- 1 Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
- 1 Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
- Histology Positive Control Tissue
- Colon or breast carcinoma
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgG2a Negative Control:FITC | MCA929F | 100 Tests | F | ||
| Mouse IgG2a Negative Control:RPE | MCA929PE | 100 Tests | F |
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Human Seroblock | BUF070A | 50 Test | F | ||
| Human Seroblock | BUF070B | 200 Test | F | ||
| Human Seroblock | BUF070A | 50 Test | F | ||
| Human Seroblock | BUF070B | 200 Test | F | ||
| Human Seroblock | BUF070A | 50 Test | F | ||
| Human Seroblock | BUF070B | 200 Test | F |
Product Specific References
References for p53 antibody
-
Vojtěsek B et al. (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.
J Immunol Methods. 151 (1-2): 237-44. -
Sironi, G. et al. (1999) p53 protein expression in conjunctival squamous cell carcinomas of domestic animals.
Vet Ophthalmol. 2 (4): 227-231. -
Levesque, M.A. et al. (1995) Time-resolved immunofluorometric assay of p53 protein.
Clin Chem. 41 (12 Pt 1): 1720-9. -
Bonsing, B.A. et al. (1997) Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
Cytometry. 28 (1): 11-24. -
Carvalho, T. et al. (2009) Immunohistochemical evaluation of vascular urinary bladder tumors from cows with enzootic hematuria.
Vet Pathol. 46 (2): 211-21. -
Phillips, A. et al. (2010) HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
J Biol Chem. 285 (38): 29111-27. -
Bergman, L.M. et al. (2009) CtBPs promote cell survival through the maintenance of mitotic fidelity.
Mol Cell Biol. 29: 4539-51. -
Hietanen, S. et al. (2000) Activation of p53 in cervical carcinoma cells by small molecules.
Proc Natl Acad Sci U S A. 97 (15): 8501-6. -
Phelps, M. et al. (2003) p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Cancer Res. 63: 2616-23.
